Publications Update # 111
In praise of bullshit, ADC list and the payloads discussion, New ESTRO-ESGO-ESP 2025 endometrial guidelines, role of stents during radical hysterectomy and RAMP-201 study summary.
Shitanshu Uppal
RAMP-201
Avutometinib 3.2 mg BIW + defactinib 200 mg BID (3-weeks-on/1-week-off) produced clinically meaningful and durable responses with manageable toxicity in recurrent LGSOC
Special July/August Edition
New Academic Year
Long-term readers of this newsletter know
Publications Update # 110
"When Death Came to Visit," a poem by Andrea Gibson, BRCA and STIC pathology, Diverting loop ileostomy in ovarian cancer, endometrial cancer conversion rates for robotic surgery, and cancer management guidelines in pregnancy.
Publications Update # 109
Everyones the hero of their own story, management of contralateral groin in vulvar cancer (with video), non-myoinvasive uterine papillary serous carcinoma with positive washings.
Publications Update # 108
An article on insomnia, question of the week (C. Diff testing), fertility preservation outcomes in CAH/G1EC, immunotherapy in transplant patients, and FDA review of PARP inhibitors.
Publications Update # 107
A discussion on how to cure loneliness in the US, Phase 2 trial - Most Circuit - Ipi/Nivo in clear cell cancer, camrelizumab and Famitinb in cervical cancer, impact of prior radiation on immunotherapy drugs, and HRT in young patients.
XIA-2025: Camrelizumab + Famitinib vs Camrelizumab vs Chemotherapy in Recurrent/Metastatic Cervical Cancer (Randomized Phase II)
Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.
Publications Update # 106
MAPK/FAK Clamp - RAMP 201 Avutomentinib and Defactinib in Low Grade Ovarian, IP chemotherapy question, ROSELLA Trial and PROFECTA-II Trial, Palliative Oophorectomy in gastric cancers
ROSELLA (GOG-3073/ENGOT-ov72): Relacorilant plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.